GLI1 and cancer: Arsenic trioxide (ATO), a Gli1/2 suppressor, is the first FDA approved drug that targeted the Hh pathway to treat acute promyelocytic leukemia ATO and currently undergoing preclinical testing for a variety of cancers, including prostate and colon cancer (Rimkus et al., 2016; Carpenter and Ray, 2019).